Balchem Corporation 2005 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2005. Balchem Corporation develops, manufactures, and markets specialty performance ingredients for the food, nutritional, feed, pharmaceutical, and medical sterilization industries. The Company operates through three segments: Specialty Products (sterilization gases), Encapsulated/Nutritional Products (microencapsulation and choline products), and BCP Ingredients (choline chloride for animal feed).
Key Financial Metrics
| Metric | 2005 | 2004 | Change |
|---|---|---|---|
| Net Sales | $83,095,000 | $67,406,000 | +23.3% |
| Gross Margin | $28,680,000 | $23,806,000 | +20.5% |
| Gross Margin % | 34.5% | 35.3% | -0.8 pts |
| Net Earnings | $10,954,000 | $8,026,000 | +36.5% |
| Diluted EPS | $0.91 | $0.69 | +31.9% |
| Operating Cash Flow | $13,698,000 | $12,145,000 | +12.8% |
| Total Assets | $75,141,000 | $60,405,000 | +24.4% |
| Long-Term Debt | $0 | $0 | N/A |
| Cash & Equivalents | $12,996,000 | $12,734,000 | +2.1% |
Note: All figures in thousands except per share data. Debt was paid in full in December 2004.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased $15.7 million, driven by a 31.3% surge in the Encapsulated/Nutritional segment (partially due to the Loders Croklaan acquisition) and a 52.5% jump in BCP Ingredients.
- Acquisitions: The Company acquired assets from Loders Croklaan USA, LLC in June 2005 for approximately $11.4 million, adding pharmaceutical and food business lines.
- Margin Pressure: Gross margin percentage declined slightly to 34.5% from 35.3% due to rising raw material and energy costs, despite volume growth.
- Stock Split: A 3-for-2 stock split was approved in December 2005 and effected in January 2006; historical per-share data has been retroactively adjusted.
Guidance, Outlook, and Risks
- Subsequent Acquisition: In February 2006, Balchem acquired Chelated Minerals Corporation (CMC) for $17.35 million, funded by cash and a new $10 million term loan.
- Debt Financing: A new credit facility was established in February 2006, including a $10 million term loan (maturing 2009) and a $3 million revolving line.
- Regulatory Risks: The Company is undergoing EPA re-registration for ethylene oxide (a key sterilant). While management expects approval, the process involves potential restrictions or additional testing.
- Customer Concentration: One customer in the specialty products segment accounted for approximately 9% of 2005 net sales.
- Legal Proceedings: A significant product liability lawsuit regarding ethylene oxide exposure was dismissed against Balchem in February 2006, though ancillary indemnification claims remain.
- Capital Expenditures: Projected to be approximately $2.3 million for 2006 (excluding CMC acquisition assets).
Investor Verification Checklist
- EPA Re-registration Status: Verify the final outcome of the ethylene oxide re-registration process and any imposed usage restrictions.
- CMC Integration: Monitor the financial performance and integration of the Chelated Minerals Corporation acquisition post-closing.
- Raw Material Costs: Assess the ability to pass on rising raw material and energy costs to customers to protect gross margins.
- Customer Concentration: Review the stability of the relationship with the single customer representing ~9% of sales.
- Stock-Based Compensation: Note the upcoming adoption of SFAS 123(R) in 2006, which will require expensing stock options, potentially reducing reported net income.